Nextage Therapeutics Valuation
| MCTC Stock | ILA 73.30 1.60 2.14% |
At this time, the firm appears to be overvalued. Nextage Therapeutics secures a last-minute Real Value of 60.82 per share. The latest price of the firm is 73.3. Our model forecasts the value of Nextage Therapeutics from analyzing the firm fundamentals such as Operating Margin of (9.71) %, return on asset of -0.37, and Shares Owned By Insiders of 22.39 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Nextage Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Nextage Therapeutics is based on 3 months time horizon. Increasing Nextage Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nextage Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nextage Stock. However, Nextage Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 73.3 | Real 60.82 | Hype 73.3 |
The real value of Nextage Stock, also known as its intrinsic value, is the underlying worth of Nextage Therapeutics Company, which is reflected in its stock price. It is based on Nextage Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Nextage Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Nextage Therapeutics helps investors to forecast how Nextage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nextage Therapeutics more accurately as focusing exclusively on Nextage Therapeutics' fundamentals will not take into account other important factors: Nextage Therapeutics Total Value Analysis
Nextage Therapeutics is now forecasted to have takeover price of 0 with market capitalization of 9.54 M, debt of 0, and cash on hands of 358 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Nextage Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 9.54 M | 0 | 358 K |
Nextage Therapeutics Investor Information
About 22.0% of the company outstanding shares are owned by corporate insiders. The book value of Nextage Therapeutics was now reported as 0.9. The company recorded a loss per share of 0.24. Nextage Therapeutics last dividend was issued on the 9th of June 2003. The entity had 1:20 split on the 12th of April 2020. Based on the key indicators related to Nextage Therapeutics' liquidity, profitability, solvency, and operating efficiency, Nextage Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Nextage Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nextage Therapeutics has an asset utilization ratio of 4.95 percent. This suggests that the Company is making 0.0495 for each dollar of assets. An increasing asset utilization means that Nextage Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Nextage Therapeutics Ownership Allocation
Nextage Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.Nextage Therapeutics Profitability Analysis
The company reported the revenue of 297 K. Net Loss for the year was (2.09 M) with profit before overhead, payroll, taxes, and interest of 207 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Nextage Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Nextage Therapeutics and how it compares across the competition.
About Nextage Therapeutics Valuation
The stock valuation mechanism determines Nextage Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Nextage Therapeutics. We calculate exposure to Nextage Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nextage Therapeutics's related companies.Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
8 Steps to conduct Nextage Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Nextage Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Nextage Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Nextage Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Nextage Therapeutics' revenue streams: Identify Nextage Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Nextage Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Nextage Therapeutics' growth potential: Evaluate Nextage Therapeutics' management, business model, and growth potential.
- Determine Nextage Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Nextage Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |